Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

BioCardia, Inc. BCDAW NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
25/100
0/4 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

BioCardia, Inc. (BCDAW) is a Biotechnology company in the Healthcare sector, currently trading at $0.01. It has a SharesGrow Score of 22/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Net income is $8M (loss), growing at +10.2%/yr. Net profit margin is 0% (thin). Gross margin is -7463.8% (-6683.5 pp trend).

Balance sheet: total debt is $528,000 against $895,000 equity (Debt-to-Equity (D/E) ratio 0.59, moderate). Current ratio is 1.12 (adequate). Debt-to-assets is 15.5%. Total assets: $3M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 48/100 (Partial), Past 0/100 (Fail), Health 50/100 (Partial), Moat 0/100 (Fail), Future ?/100 (Fail), Income ?/100 (Fail).

BCDAW SharesGrow Score Overview

49/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 48/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 0/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — BCDAW

—
VALUE N/A
N/A
No analyst coverage available for this stock.
~
GROWTH Partial
48/100
BCDAW: -84.2%/yr revenue is, +10.2%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
50/100
Balance sheet BCDAW: Debt-to-Equity (D/E) ratio 0.59 (moderate), Current ratio is 1.12 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
—
MOAT N/A
N/A
No analyst coverage available for this stock.
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.0061-0.0063
Volume18.71K
Market Cap$10.12K
Beta (1Y)1.37
Share Statistics
EPS (TTM)-1.23
Shares Outstanding$6.67M
IPO Date2019-08-02
Employees16
CEOPeter A. Altman
Financial Highlights & Ratios
Gross Profit$-505K
EBITDA$-7.77M
Net Income$-8.23M
Operating Income$-8.28M
Total Cash$2.5M
Total Debt$528K
Net Debt$-1.97M
Total Assets$3.41M
Price / Earnings (P/E)-0
Analyst Forecast
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS09060U1198

Price Chart

Track all markets on TradingView
BCDAW
BioCardia, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
0.01 52WK RANGE 0.01

People Also View

XBIOW
XBIOW
Xenetic Biosciences, Inc.
$17.54
-23.54%
 IMACW
IMACW
IMAC Holdings, Inc.
$0.01
+10.09%
 ARTLW
ARTLW
Artelo Biosciences, Inc.
$0.01
+0.00%
 ADILW
ADILW
Adial Pharmaceuticals, Inc. WT EXP 073123
$0.00
-57.14%
 ENTXW
ENTXW
Entera Bio Ltd. WT EXP 062723
$0.00
-60.00%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message